GTx (NASDAQ:GTXI) Earning Favorable Media Coverage, Report Finds

Media coverage about GTx (NASDAQ:GTXI) has trended positive on Sunday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTx earned a coverage optimism score of 0.32 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.2351865340366 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

GTx (GTXI) traded up 1.28% during midday trading on Friday, hitting $7.92. The stock had a trading volume of 3,806 shares. The company’s market cap is $127.19 million. GTx has a 52 week low of $2.73 and a 52 week high of $9.90. The stock’s 50 day moving average price is $8.03 and its 200-day moving average price is $5.70.

GTx (NASDAQ:GTXI) last posted its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter. Equities research analysts predict that GTx will post ($1.16) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.truebluetribune.com/2017/10/22/gtx-gtxi-getting-positive-news-coverage-study-shows.html.

About GTx

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply